Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines Yuqian LiuRuochen ZangWenbao Li PRECLINICAL STUDIES 04 December 2019 Pages: 1207 - 1217
W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors Dong LiangHong-Ying WangWei Han PRECLINICAL STUDIES 10 December 2019 Pages: 1218 - 1226
Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma Chengbin ZhaoYuyuan GaoBo Yang PRECLINICAL STUDIES 10 December 2019 Pages: 1227 - 1235
[HuArgI (co)-PEG5000]-induced arginine deprivation leads to autophagy dependent cell death in pancreatic cancer cells Nathalie KhalilRalph J. Abi-Habib PRECLINICAL STUDIES 10 December 2019 Pages: 1236 - 1246
Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells Jie HuEnxin WangGuohong Han PRECLINICAL STUDIES 13 December 2019 Pages: 1247 - 1256
Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells Mona OliveiraLourenço Luis Botelho de SantanaSilvio Cunha PRECLINICAL STUDIES 14 December 2019 Pages: 1257 - 1271
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models Li WangChen HuQingsong Liu PRECLINICAL STUDIES 23 December 2019 Pages: 1272 - 1281
KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth Jungjoong HwangInsuk SongJongkook Lee PRECLINICAL STUDIES 20 January 2020 Pages: 1282 - 1291
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells Feng QuYue GuYing Peng PRECLINICAL STUDIES 01 February 2020 Pages: 1292 - 1302
Combating atherosclerosis with targeted Diosmin nanoparticles-treated experimental diabetes Hendawy OMMehrez E. El-NaggarOsama M. Morsy PRECLINICAL STUDIES 11 February 2020 Pages: 1303 - 1315
Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology Omar AbuhusseinJian Yang PRECLINICAL STUDIES 14 February 2020 Pages: 1316 - 1325
Anticancer activity of Turkish marine extracts: a purple sponge extract induces apoptosis with multitarget kinase inhibition activity Halil I. CiftciMustafa CanMohamed O. Radwan PRECLINICAL STUDIES 15 February 2020 Pages: 1326 - 1333
Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study Tao LiDong-Dong JiaLi-Song Teng PRECLINICAL STUDIES 18 February 2020 Pages: 1334 - 1341
Dezocine promotes T lymphocyte activation and inhibits tumor metastasis after surgery in a mouse model Qiang SongGeng LiuChang Feng PHASE I STUDIES 13 March 2020 Pages: 1342 - 1349
Structure-based design, synthesis, and evaluation of the biological activity of novel phosphoroorganic small molecule IAP antagonists Agnieszka Łupicka-SłowikMateusz PsurskiMarcin Sieńczyk PRECLINICAL STUDIES Open access 08 April 2020 Pages: 1350 - 1364
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A Laura BreenPatricia B. GauleAlex J. Eustace PRECLINICAL STUDIES 22 April 2020 Pages: 1365 - 1372
Novel Bacillus strains from the human gut exert anticancer effects on a broad range of malignancy types Man-Fei ZhaoGong-Da LiangShu-Lin Liu PRECLINICAL STUDIES 31 July 2020 Pages: 1373 - 1382
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma Ana M. MolinaJohannes C. van der MijnLorraine J. Gudas PHASE I STUDIES 03 January 2020 Pages: 1383 - 1389
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies Toshihiko DoiNarikazu BokuAtsushi Ohtsu PHASE I STUDIES Open access 06 January 2020 Pages: 1390 - 1399
A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer Sagar SardesaiMohamed BadawiRobert Wesolowski PHASE I STUDIES 17 January 2020 Pages: 1400 - 1410
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients Alberto A. GabizonEsther TahoverPatricia Ohana PHASE I STUDIES 18 January 2020 Pages: 1411 - 1420
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma David C. SmithMatthias KroissAung Naing PHASE I STUDIES 27 January 2020 Pages: 1421 - 1429
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia Geoffrey L. UySarit AssoulineKaren Yee PHASE I STUDIES Open access 04 February 2020 Pages: 1430 - 1441
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies J. NehraP. A. BradburyM. Smoragiewicz PHASE I STUDIES 04 February 2020 Pages: 1442 - 1447
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma Eric K. RowinskyAgne PanerOla Landgren PHASE I STUDIES Open access 03 March 2020 Pages: 1448 - 1453
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer K. Esther BroekmanMarieke A. J. HofMathilde Jalving PHASE I STUDIES Open access 07 March 2020 Pages: 1454 - 1462
Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients Vissia VigliettaFuxin ShiJohn Soglia PHASE I STUDIES Open access 10 March 2020 Pages: 1463 - 1471
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Frank KroschinskyJan Moritz MiddekeNorbert Schmitz PHASE I STUDIES Open access 14 March 2020 Pages: 1472 - 1482
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR James M. ClearyEmiliano CalvoAnthony W. Tolcher PHASE I STUDIES 18 March 2020 Pages: 1483 - 1494
First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors Naohiro OkanoDaisuke NarugeJunji Furuse PHASE I STUDIES 20 March 2020 Pages: 1495 - 1506
Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers Andreas JohneHolger ScheibleMichael Meyring PHASE I STUDIES Open access 27 March 2020 Pages: 1507 - 1519
Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors Nataliya V. UbohaSam J. LubnerDustin A. Deming PHASE I STUDIES 06 April 2020 Pages: 1520 - 1525
Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir Huixin YuJulie M. JanssenAlwin D. R. Huitema PHASE I STUDIES 19 April 2020 Pages: 1526 - 1532
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer Lipika GoyalSurendra Pal ChaudharyJeffrey W. Clark PHASE II STUDIES 02 January 2020 Pages: 1533 - 1539
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting Kenichi InoueMasato TakahashiJunji Tsurutani PHASE II STUDIES Open access 16 January 2020 Pages: 1540 - 1549
A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma Paul L. SwiecickiGreg DurmFrancis P. Worden PHASE II STUDIES 24 January 2020 Pages: 1550 - 1558
Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma Zhichao TianHuimin LiuJiaqiang Wang PHASE II STUDIES Open access 25 February 2020 Pages: 1559 - 1569
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma Antje WickAnnick DesjardinsJordi Rodon PHASE II STUDIES Open access 05 March 2020 Pages: 1570 - 1579
Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial Soledad IseasEnrique L. RocaDaniel F. Alonso PHASE II STUDIES Open access 12 March 2020 Pages: 1580 - 1587
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer Nobuyuki YamamotoHidetoshi HayashiSusana Cedres PHASE II STUDIES Open access 03 April 2020 Pages: 1588 - 1597
Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia Satoko OkaKazuo OnoMasaharu Nohgawa SHORT REPORT 22 January 2020 Pages: 1598 - 1600
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis Jean-Michel LavoieTeresa MitchellDaniel J. Renouf Short Report 06 January 2020 Pages: 1601 - 1604
Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience Anupama SureshAkannsha GanjuNicole Williams Short Report 14 January 2020 Pages: 1605 - 1611
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer Hiroto InoueAkira OnoToshiaki Takahashi Short Report Open access 03 March 2020 Pages: 1612 - 1617
Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood Holly A. MaulhardtAlyson M. MarinGere S. diZerega Short Report Open access 20 March 2020 Pages: 1618 - 1626
Dasatinib-induced chylothorax: report of a case and review of the literature Bojiang ChenZuohong WuDeyun Cheng Short Report 04 April 2020 Pages: 1627 - 1632